報價延遲最少15分鐘:2025/07/29 01:15 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.75 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.44/-1.90
|
|
企業價值
266.91M
|
| 資產負債 |
|
每股賬面淨值
2.64
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/07/29 01:15 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade's pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. |
